On October 16, 2025, Henry Schein, Inc. (HSIC) and Biomerica, Inc. (BMRA) announced a marketing services arrangement. The partnership focuses on promoting Biomerica’s inFoods® IBS Test, a non‑drug diagnostic solution for irritable bowel syndrome symptom management. The agreement positions Henry Schein as the primary marketing partner for the test across its extensive network of office‑based dental and medical practitioners.
Henry Schein’s role will involve leveraging its global distribution and customer relationships to increase awareness and adoption of the inFoods test. By integrating the test into its existing product portfolio, Henry Schein can expand its service offerings beyond traditional medical and dental supplies. The arrangement is expected to generate additional revenue streams for Henry Schein through marketing fees and potential sales commissions.
This collaboration aligns with Henry Schein’s strategic focus on high‑margin specialty products and technology solutions. The partnership enhances the company’s ability to serve the growing demand for non‑drug diagnostic tools in the medical market. As a result, the agreement represents a meaningful expansion of Henry Schein’s product ecosystem and reinforces its position as a comprehensive solutions provider.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.